Skip to main content
Evidence Snapshot

Alpha-1A adrenergic receptor

CHEMBL3637 SINGLE PROTEIN Oryctolagus cuniculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:36:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3637
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-1A adrenergic receptor as ChEMBL target CHEMBL3637, mapped to UniProt O02824. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-1A adrenergic receptor
SINGLE PROTEIN · Oryctolagus cuniculus
As of 2026-09-13
ChEMBL target ID
CHEMBL3637
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O02824
Alpha-1A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Alpha-1A adrenergic receptor matters

As of 2026-09-13

Alpha-1A adrenergic receptor is reviewed as Alpha-1A adrenergic receptor (UniProt O02824); the current evidence base includes 4 approved drugs, 137 compounds, and 12 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 137 compounds, and 12 assays for this target. The dominant activity type is KD. CHEMBL314880 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL314880 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Alpha-1A adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O02824, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

137
Total Compounds
12
Total Assays
4
Approved Drugs
EC50: 18.0, KD: 61.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL314880
 10.7 Kd —
No preferred name
CHEMBL330579
 10.0 Kd —
No preferred name
CHEMBL313775
 10.0 Kd —
No preferred name
CHEMBL327231
 9.9 Kd —
No preferred name
CHEMBL91278
 9.8 Kd —

Approved Drugs

Structure Compound First Approval
TAMSULOSIN
CHEMBL836
 1997
TERAZOSIN
CHEMBL611
 1987
PRAZOSIN
CHEMBL2
 1976
PHENTOLAMINE
CHEMBL597
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:36:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3637